A phase 1/2 study of NS-018, an oral JAK2 inhibitor, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV MF), or post-essential thrombocythemia myelofibrosis (PET MF)

Authors
Category Primary study
JournalBlood
Year 2015
This article has no abstract
Epistemonikos ID: 970255a36cd5f490d3a474f659d485a77f4ef831
First added on: Feb 07, 2025